<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Menopause — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Menopause</h1>
        <div class="sub">Primary care quick page: recognise perimenopause/menopause, offer first-line management (incl HRT and non-hormonal options), and know when/where to refer. Cross-links to bleeding on HRT.</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑09</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>Key points (NICE NG23)</strong>
                <ul>
                  <li>In <strong>otherwise healthy people aged ≥45</strong> with typical symptoms, diagnose <strong>perimenopause/menopause clinically</strong> (do not use routine labs).</li>
                  <li><strong>FSH testing</strong> is generally only for <strong>age 40–45</strong> with symptoms (incl cycle change), <strong>early menopause</strong> (age 40–44), or <strong>premature ovarian insufficiency (POI)</strong> (&lt;40).</li>
                  <li><strong>HRT is first-line</strong> for bothersome <strong>vasomotor symptoms</strong> (hot flushes/night sweats) where no contraindication.</li>
                  <li><strong>Menopause-specific CBT</strong> is an option for vasomotor symptoms (adjunct to HRT, or when HRT is contraindicated or not wanted).</li>
                  <li><strong>Genitourinary syndrome of menopause (GSM)</strong>: vaginal oestrogen is effective; serious adverse effects are very rare; symptoms often recur on stopping, but can restart.</li>
                </ul>
              </div>

              <h4>Recognising perimenopause/menopause (practical)</h4>
              <ul>
                <li><strong>Perimenopause</strong> (≥45): new vasomotor symptoms + any menstrual cycle change → clinical diagnosis (no labs needed).</li>
                <li><strong>Menopause</strong> (≥45): no period ≥12 months (and not using hormonal contraception) → clinical diagnosis.</li>
                <li>After <strong>hysterectomy</strong>: menopause is identified by symptom pattern (for example vasomotor symptoms).</li>
                <li>It can be difficult to identify menopause in people taking hormonal treatments (for example for HMB) — treat individually.</li>
              </ul>

              <h4>What not to do (NICE)</h4>
              <ul>
                <li>Do not use AMH, inhibin A/B, oestradiol, antral follicle count, ovarian volume to identify menopause/perimenopause in ≥45.</li>
                <li>Do not use FSH to identify menopause in people using <strong>combined hormonal contraception</strong> or <strong>high-dose progestogen</strong>.</li>
                <li>Do not routinely offer <strong>SSRI/SNRI</strong> or <strong>clonidine</strong> as <strong>first-line</strong> treatment for vasomotor symptoms alone.</li>
              </ul>

              <h4>First-line management themes (primary care)</h4>
              <ul>
                <li><strong>Shared decision making</strong> about symptom priorities, HRT benefits/risks, and alternatives; review and adjust.</li>
                <li><strong>Contraception</strong>: perimenopause ≠ no fertility. Ensure contraception advice (FSRH over-40 guidance).</li>
                <li><strong>Bone and muscle health</strong>: discuss bone health; encourage physical activity/strength maintenance.</li>
                <li><strong>Bleeding on HRT</strong>: manage via the dedicated pathway (triage thresholds differ by regimen/risk). See: <a href="./bleeding-on-hrt.html">Unscheduled bleeding on HRT</a>.</li>
              </ul>

              <div class="callout warn">
                <strong>Local (D&amp;G) — still to confirm</strong>
                <ul>
                  <li>Whether there is a specific <strong>Menopause clinic</strong> referral route (vs General Gynae) for complex symptoms / complex HRT prescribing.</li>
                  <li>Preferred local approach to <strong>baseline risk assessment</strong> before starting HRT (e.g., VTE/CVD risk, BP, BMI, breast screening status) and follow-up intervals.</li>
                </ul>
              </div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">
            <div id="draftText" class="section">
              <h3>DGRefHelp draft (D&amp;G) — Menopause</h3>

              <h4>Background</h4>
              <ul>
                <li>Menopause/perimenopause commonly occurs in mid-life, but can occur earlier (including after surgery/medical treatment).</li>
                <li>Symptoms vary in type and duration: cycle change, vasomotor symptoms, mood change, musculoskeletal symptoms, sexual difficulties, and genitourinary symptoms (vaginal dryness/urinary symptoms).</li>
                <li>Priority is symptom control, health promotion (bone/muscle, cardiovascular risk factors), contraception advice, and identifying people who need specialist input (early menopause/POI, complex comorbidity, malignancy red flags).</li>
              </ul>

              <h4>Assessment (primary care)</h4>
              <ul>
                <li><strong>Symptoms:</strong> vasomotor (frequency/severity), sleep, mood, cognitive symptoms, joint/muscle pain, sexual function, GSM symptoms (dryness, dyspareunia, recurrent UTI-type symptoms).</li>
                <li><strong>Menstrual/bleeding pattern:</strong> changes in cycle length/regularity; bleeding on HRT if applicable (see bleeding-on-HRT page).</li>
                <li><strong>Contraception:</strong> current method; pregnancy risk; whether hormonal contraception may mask bleeding pattern.</li>
                <li><strong>Risk factors / contraindications to HRT:</strong> past VTE, cardiovascular disease/stroke, active liver disease, migraine with aura (route considerations), breast cancer history, unexplained vaginal bleeding.</li>
                <li><strong>Baseline observations:</strong> BP, BMI; consider CVD risk factor review and bone health discussion.</li>
              </ul>

              <h4>Diagnosis — when to test</h4>
              <ul>
                <li><strong>Age ≥45</strong> with typical symptoms: diagnose perimenopause/menopause clinically (no routine labs).</li>
                <li><strong>FSH</strong> can be considered to confirm menopause only in:
                  <ul>
                    <li>age <strong>40–45</strong> with symptoms (incl cycle change),</li>
                    <li><strong>early menopause</strong> age 40–44,</li>
                    <li><strong>POI</strong> (&lt;40; needs specialist framing).</li>
                  </ul>
                </li>
                <li><strong>Do not</strong> use FSH to diagnose menopause if on combined hormonal contraception or high-dose progestogen.</li>
              </ul>

              <h4>Primary care management</h4>
              <ul>
                <li><strong>Vasomotor symptoms:</strong> offer <strong>HRT</strong> if appropriate. If HRT is contraindicated or not wanted, consider <strong>menopause-specific CBT</strong>.</li>
                <li><strong>GSM:</strong> offer <strong>vaginal oestrogen</strong> (cream/gel/tablet/pessary/ring) via shared decision making. Explain serious adverse effects are very rare; symptoms often recur when stopped; can restart if needed.</li>
                <li><strong>Do not</strong> routinely use SSRI/SNRI or clonidine as first-line for vasomotor symptoms alone.</li>
                <li><strong>Health promotion:</strong> discuss bone health; encourage physical activity/strength maintenance; address smoking/alcohol and weight where relevant; signpost to reputable resources.</li>
                <li><strong>Contraception:</strong> provide contraception advice / signpost to FSRH over‑40 guidance.</li>
              </ul>

              <h4>Who to refer</h4>
              <ul>
                <li><strong>Premature ovarian insufficiency (POI) / suspected menopause &lt;40</strong> → specialist assessment (typically gynae/endocrine per local route).</li>
                <li><strong>Early menopause (40–44)</strong> with significant distress or complex management needs.</li>
                <li><strong>Symptoms not controlled</strong> after reasonable primary-care management trials, or <strong>complex comorbidity/contraindications</strong> where specialist input is needed.</li>
                <li><strong>Personal history of breast cancer</strong> and menopause-associated symptoms → specialist pathway (usually oncology/breast + menopause expertise; local route to agree).</li>
                <li><strong>Unexplained vaginal bleeding</strong> or <strong>bleeding on HRT</strong> that meets referral thresholds → use bleeding pathways:
                  <ul>
                    <li><a href="./bleeding-on-hrt.html">Unscheduled bleeding on HRT</a></li>
                    <li><a href="./postmenopausal-bleeding.html">Postmenopausal bleeding</a></li>
                    <li><a href="./abnormal-uterine-bleeding.html">Abnormal uterine bleeding</a></li>
                  </ul>
                </li>
              </ul>

              <h4>Safety-net / when to reassess urgently</h4>
              <ul>
                <li>New, heavy, persistent, or postcoital bleeding (especially &gt;45 or postmenopausal) → assess for malignancy risk and use the relevant bleeding pathway.</li>
                <li>New unilateral breast lump, nipple change, or other concerning breast symptoms → urgent breast pathway.</li>
                <li>New severe headache/neurological symptoms, chest pain, shortness of breath, unilateral leg swelling while on systemic HRT → urgent assessment for thromboembolic/cardiovascular events.</li>
              </ul>

              <h4>Local agreement needed (drafting-site only)</h4>
              <ul>
                <li><label><input type="checkbox" disabled /> Preferred destination for complex menopause/HRT issues: <strong>Menopause clinic</strong> vs <strong>General Gynae</strong> (and referral criteria).</label></li>
                <li><label><input type="checkbox" disabled /> Local expectations for <strong>baseline assessment</strong> and <strong>monitoring</strong> when starting/changing HRT (including who does what and at what interval).</label></li>
                <li><label><input type="checkbox" disabled /> Local approach for menopause symptoms in people with a <strong>history of breast cancer</strong> (referral route + whether vaginal oestrogen can be initiated in primary care vs specialist-led).</label></li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References</h3>
              <ul>
                <li>NICE. <em>Menopause: identification and management</em> (NG23). Last updated 7 Nov 2024. https://www.nice.org.uk/guidance/ng23 (retrieved 2026‑02‑09).</li>
                <li>FSRH. <em>Contraception for women aged over 40 years</em> (guidance). https://www.fsrh.org/standards-and-guidance/documents/contraception-for-women-aged-over-40-years/ (retrieved 2026‑02‑09).</li>
              </ul>
            </div>
          </div>

        </div>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
